Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.65 |
| ▸ | GSK3B | P49841 | 7/20 | 0.65 |
| ▸ | CLK2 | P49760 | 6/20 | 0.65 |
| ▸ | KDR | P35968 | 5/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.65 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.65 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.65 |
| ▸ | CDK2 | P24941 | 3/20 | 0.65 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.65 |
| ▸ | STK3 | Q13188 | 3/20 | 0.65 |
| ▸ | PBK | Q96KB5 | 3/20 | 0.65 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.65 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.65 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 0.65 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12032927 | 0.80 | CCNC (0.59) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL31060264 | 0.79 | CLK4 (1.00) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL3797148 | 0.79 | CLK4 (1.00) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL27902526 | 0.79 | CCNC (0.58) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL12095894 | 0.78 | SLC22A12 (0.58) | RIPK2CDK8CCNCABL1GAK | |
| SCHEMBL26965922 | 0.78 | LMNA (0.56) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL30120710 | 0.78 | LMNA (0.56) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL29822887 | 0.77 | GAK (0.57) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL27299059 | 0.76 | CLK4 (0.63) | CLK4GSK3BCLK2KDRPRKD3 | |
| SCHEMBL3804165 | 0.76 | CLK4 (0.67) | CLK4GSK3BCLK2KDRPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CLK4 3506/4885GSK3B 4566/4885CLK2 2786/4885 |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CLK4 3506/4885GSK3B 4566/4885CLK2 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.